European Lung Cancer Congress 2025
The European Lung Cancer Congress 2025, held March 26-29, in Paris, France, features critical updates across the field of thoracic oncology.
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
PALOMA-2 used data from PALOMA-3 to evaluate subcutaneous versus intravenous amivantamab for EGFR-mutated NSCLC.
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Dr. Ladanyi reflects on genetic hotspot mutations that have not been previously well characterized in lung adenocarcinoma.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Suresh Senan, MRCP, FRCR, PhD, presented the data at the European Lung Cancer Congress 2025 in Paris, France.
Martin Reck, MD, PhD, presented the final analysis at the European Lung Cancer Congress 2025.
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
Marina Garassino, MD, presented results from the phase 2 portion of the trial at the European Lung Cancer Congress.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Myung-Ju Ahn, MD, PhD, presented data from the study during the first proffered paper session of ELCC 2025.
Nicolas Girard, MD, PhD, of Institut Curie, presented the findings from expansion cohorts of the study at ELCC 2025.
Xiuning Le, MD, PhD, presented results from the ORCHARD trial at ELCC 2025.
The award recognizes his "exceptional contributions to thoracic oncology research and education."
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.